ES2646320T3 - Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo - Google Patents
Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo Download PDFInfo
- Publication number
- ES2646320T3 ES2646320T3 ES10715098.9T ES10715098T ES2646320T3 ES 2646320 T3 ES2646320 T3 ES 2646320T3 ES 10715098 T ES10715098 T ES 10715098T ES 2646320 T3 ES2646320 T3 ES 2646320T3
- Authority
- ES
- Spain
- Prior art keywords
- glycan
- jejuni
- wbap
- salmonella enterica
- presents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/105—Delta proteobacteriales, e.g. Lawsonia; Epsilon proteobacteriales, e.g. campylobacter, helicobacter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Virology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Salmonella enterica, caracterizada por que comprende al menos un operón pgl (para la glicosilación de proteínas) de Campylobacter jejuni o un derivado funcional del mismo y presenta sobre su superficie celular al menos un N-glicano de Campylobacter jejuni o un derivado de N-glicano del mismo, en donde están inactivados uno más genes de la biosíntesis de bacilosamina por mutación y/o deleción parcial o completa, preferiblemente por deleción parcial y/o completa de los genes pgI, D, E, F.
Description
Capacidad de colonización de ∆wbaP en un experimento de co-infección
La capacidad de colonización de S. Typhimurium ∆wbaP se probó en un experimento de co-infección en el cual los ratones se infectaron intragástricamente con el mutante ∆wbaP, así como con la cepa tipo silvestre. Los ratones 5 C57BL/6 (SPF, colonia del RCHCl, Zurich) se pre-trataron mediante sonda gástrica con 20 mg de estreptomicina. Veinticuatro horas después los ratones se inocularon con 5 x 107 UFC de la cepa serovar Typhimurium o las mezclas de las cepas como se indica. Las cargas bacterianas (UFC) en sedimentos fecales frescos, nodos linfoides mesentéricos (mLN), bazo, y contenido cecal se determinaron mediante la siembra en placas sobre placas de agar MacConkey (50 µg/ml de estreptomicina) como se ha descrito anteriormente (Barthel, Hapfelmeier et al. 2003). Los 10 índices competitivos (CI) se determinaron de acuerdo con la fórmula CI= (mutante/tipo silvestre) salida/(mutante/tipo silvestre) entrada después de la siembra en placa. Se realizó un experimento de co-infección de serovar Typhimurium tipo silvestre (M939) y la cepa ∆wbaP (SKI11). Cinco ratones tratados con estreptomicina se infectaron con una mezcla 1:2 (total 5 X 107 UFC) intragástricamente de la cepa ∆wbaP (SKI11) y la cepa tipo silvestre. La proporción de las 2 cepas (CI; índice competitivo, véase Materiales y Métodos) se determinó en las heces en el día 15 1, 2 y 3 p.i. Se detectó una disminución de los recuentos de ∆wbaP (SKI11) en comparación con el tipo silvestre (una escala logarítmica por día) y se probó que la cepa ∆wbaP (SKI11) de hecho tuvo un defecto competitivo importante en comparación con la cepa serovar Typhimurium tipo silvestre en el tracto intestinal (p>0,05; figura 4A). Además, el CI de las dos cepas en los sitios sistémicos (mLN, hígado, bazo) en el día 4 p.i. también demostró un defecto competitivo significativo de serovar Typhimurium ∆wbaP (SKI12). Sin embargo, el defecto era menos
20 pronunciado que en el intestino (Figura 4B).
Tabla 1: Cepas, plásmidos y cebadores para la deleción de wbaP utilizados en este trabajo
- Cepas de Salmonella enterica sv Typhimurium
- Cepa
- Genotipo y fenotipo Fuente de la referencia
- SL1344
- tipo silvestre; strepR Hoiseth, S. K. and B. A. Stocker, Nature 291:238-239, 1981
- SKI11
- SL1344∆wbaP::cat; strepR , cam R este estudio
- SKI12
- SL1344∆wbaP; strepR este estudio
- SKI34
- SKI12::pKI14; strepR, tetR este estudio
- SKI35
- SKI12::pKI15; strepR, tetR este estudio
- Cepas de Escherichia coli
- DH5a
- SupE44 ∆lacU169 (Φ80lacZ∆M15) hsdR17 recA1 endA1 gyrA96 thi-1 relA1 Hanahan, D., J. Mol. Biol., 5,166(4):557-80, 1983
- CC118 λpir
- ∆(ara-leu), araD, ∆lacX74, galE, galK, phoA20, thi-1, rpsE, rpoB, argE(Am), recA, λpir Herrero, M., V. de Lorenzo, and K. N. Timmis. J Bacteriol 172:6557-6567.
- Sm10λpir
- thi thr leu tonA lacY supE recA::RP4 2-Tc::Mu λpir, kanR Miller, V. L. and J. J. Mekalanos. J. Bacteriol. 170:2575-2583, 1988.
- Plásmidos
- Plásmido
- Genotipo Fuente de referencia
- pSB377
- tetR oriR6K Mirold et al., Proc. Natl. Acad. Sci. USA, 96:9845-9850, 1999.
- pKD3
- bla FRT cat FRT PS1 Datsenko, K. A. and B. L.
- PS2 oriR6K
- Wanner, Proc. Natl. Acad. Sci. USA, 97:6640-6645, 2000.
- pKD46
- bla PBAD gam bet exo pSC101 oriTS Datsenko, K. A., and B. L. Wanner, Proc. Natl. Acad. Sci. USA, 97:66406645, 2000.
- pCP20
- bla cat cl857 λPR flp pSC101 oriTS Datsenko, K. A., and B. L. Wanner,Proc. Natl. Acad. Sci. USA, 97:6640-6645, 2000
- pACYC184
- CmR, TcR, ori p15A New England Biolabs
- pACYCpglmut
- CmR, ori p15A; grupo C. jejuni pgl con pglBW458A,D459A clonado en pACYC184 Science, 298(5599):1790-3, 29. Nov. 2002
- pACYCpgl3mut
- CmR, ori p15A; grupo C. jejuni pgl con pglBW458A,D459A clonado en pACYC184, deleción en pglE, F, G y 3'-mitad de pglD Este estudio
- pKI14
- TetR, oriR6K, región de 500 pb 3' de PagC clonado en pSB377 Este estudio
- pKI15
- TetR, oriR6K, grupo C. jejuni pgl3mut con pglBW458A,D459A clonado en pKI15 Este estudio
- Cebadores para la delación de wbaP
- RfbP H1P1
12
Claims (1)
-
imagen1 imagen2
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09004445 | 2009-03-27 | ||
EP09004445 | 2009-03-27 | ||
PCT/EP2010/001884 WO2010108682A1 (en) | 2009-03-27 | 2010-03-25 | Salmonella enterica presenting c. jejuni n-glycan or derivatives thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2646320T3 true ES2646320T3 (es) | 2017-12-13 |
Family
ID=42199060
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES10715098.9T Active ES2646320T3 (es) | 2009-03-27 | 2010-03-25 | Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo |
Country Status (14)
Country | Link |
---|---|
US (2) | US9309493B2 (es) |
EP (1) | EP2411503B1 (es) |
JP (1) | JP5568626B2 (es) |
KR (1) | KR101395431B1 (es) |
CN (1) | CN102365359B (es) |
BR (1) | BRPI1010283B8 (es) |
CA (1) | CA2757224C (es) |
ES (1) | ES2646320T3 (es) |
IL (1) | IL215239A (es) |
MX (1) | MX2011009791A (es) |
PL (1) | PL2411503T3 (es) |
PT (1) | PT2411503T (es) |
RU (1) | RU2507253C2 (es) |
WO (1) | WO2010108682A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101855380B1 (ko) * | 2009-11-19 | 2018-05-08 | 글락소스미스클라인 바이오로지칼즈 에스.에이. | 원핵세포에서 면역원성 폴리사카라이드를 제조하는 생합성 시스템 |
WO2013034664A1 (en) * | 2011-09-06 | 2013-03-14 | Glycovaxyn Ag | Bioconjugate vaccines made in prokaryotic cells |
EP2841559A4 (en) | 2012-04-27 | 2015-12-16 | Univ Alberta | GLYCOMODIFIED EXTERNAL MEMBRANE VESICLES AND THEIR USE AS VACCINES |
RU2671473C2 (ru) * | 2013-04-05 | 2018-10-31 | Де Гавенерс Оф Де Юниверсити Оф Альберта | Вакцина против кампилобактериоза |
CN103740632B (zh) * | 2014-01-22 | 2016-02-10 | 山东大学 | 一株重组大肠杆菌及其在制备抗o157:h7的n-糖蛋白疫苗中的应用 |
CN110520153B (zh) * | 2017-01-27 | 2024-04-02 | 佛罗里达大学研究基金公司 | 在禽类中控制肠道沙门氏菌和减少弯曲杆菌的食品安全疫苗 |
CA3054765A1 (en) | 2017-03-15 | 2018-09-20 | London School Of Hygiene And Tropical Medicine | Whole cell vaccines |
PE20171768A1 (es) * | 2017-06-12 | 2017-12-21 | Farm Veterinarios S A C | Obtencion de una salmonela enteritidis tipo rugosa y sus modificaciones geneticas para uso como vacuna aviar |
US20200377620A1 (en) * | 2017-12-19 | 2020-12-03 | The Governors Of The University Of Alberta | Clostridium perfringens surface glycans and uses thereof |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6399074B1 (en) * | 1998-07-24 | 2002-06-04 | Megan Health, Inc. | Live attenuated salmonella vaccines to control avian pathogens |
HU227667B1 (en) * | 2001-05-03 | 2011-11-28 | Fit Biotech Oyj Plc | Novel expression vectors and uses thereof |
CA2494223C (en) * | 2002-08-01 | 2012-10-02 | National Research Council Of Canada | Campylobacter glycans and glycopeptides |
RU2237089C2 (ru) * | 2002-10-31 | 2004-09-27 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Рекомбинантный аттенуированный штамм бактерий salmonella enteriditis е-23/pgex-2t-tbi как кандидат для конструирования живой вакцины против вируса иммунодефицита человека |
AU2004236636B2 (en) * | 2003-03-24 | 2010-02-04 | The Scripps Research Institute | DNA vaccines against tumor growth and methods of use thereof |
RU2248396C2 (ru) * | 2003-04-17 | 2005-03-20 | Государственный научный центр вирусологии и биотехнологии "Вектор" | Рекомбинантная плазмидная днк pcdna-tci, обеспечивающая экспрессию искусственного гена tci в клетках эукариот, и рекомбинантный аттенуированный штамм бактерий salmonella enteritidis e-23/pcdna-tci как кандидат для конструирования живой днк-вакцины против вируса иммунодефицита человека |
EP1655370A1 (en) * | 2004-11-05 | 2006-05-10 | Gesellschaft für Biotechnologische Forschung | Bacterial vector |
US8753864B2 (en) * | 2005-05-11 | 2014-06-17 | Eth Zurich | Recombinant N-glycosylated proteins from procaryotic cells |
WO2007038122A2 (en) | 2005-09-21 | 2007-04-05 | The United States Of America As Represented By The Secretary Of The Navy | Immunogenic capsule composition for use as a vaccine component against campylobacter jejuni |
DE102008012452A1 (de) * | 2008-03-04 | 2009-09-10 | Tridonicatco Gmbh & Co. Kg | Schaltung zum Beheizen und Überwachen der Heizwendeln mindestens einer mit einem elektronischen Vorschaltgerät betriebenen Gasentladungslampe auf Wendelbruch |
-
2010
- 2010-03-25 RU RU2011143381/10A patent/RU2507253C2/ru active
- 2010-03-25 CA CA2757224A patent/CA2757224C/en active Active
- 2010-03-25 PL PL10715098T patent/PL2411503T3/pl unknown
- 2010-03-25 KR KR1020117021982A patent/KR101395431B1/ko active IP Right Grant
- 2010-03-25 WO PCT/EP2010/001884 patent/WO2010108682A1/en active Application Filing
- 2010-03-25 CN CN201080015941.2A patent/CN102365359B/zh active Active
- 2010-03-25 BR BRPI1010283A patent/BRPI1010283B8/pt active IP Right Grant
- 2010-03-25 EP EP10715098.9A patent/EP2411503B1/en active Active
- 2010-03-25 US US13/254,232 patent/US9309493B2/en active Active
- 2010-03-25 PT PT107150989T patent/PT2411503T/pt unknown
- 2010-03-25 ES ES10715098.9T patent/ES2646320T3/es active Active
- 2010-03-25 MX MX2011009791A patent/MX2011009791A/es active IP Right Grant
- 2010-03-25 JP JP2012501188A patent/JP5568626B2/ja active Active
-
2011
- 2011-09-19 IL IL215239A patent/IL215239A/en active IP Right Grant
-
2016
- 2016-04-08 US US15/094,537 patent/US9764021B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN102365359B (zh) | 2014-10-29 |
EP2411503A1 (en) | 2012-02-01 |
MX2011009791A (es) | 2011-10-17 |
BRPI1010283B1 (pt) | 2021-04-06 |
CN102365359A (zh) | 2012-02-29 |
JP5568626B2 (ja) | 2014-08-06 |
PT2411503T (pt) | 2017-11-15 |
BRPI1010283B8 (pt) | 2021-05-25 |
CA2757224A1 (en) | 2010-09-30 |
KR101395431B1 (ko) | 2014-05-14 |
EP2411503B1 (en) | 2017-09-13 |
WO2010108682A1 (en) | 2010-09-30 |
IL215239A (en) | 2016-02-29 |
RU2507253C2 (ru) | 2014-02-20 |
US9309493B2 (en) | 2016-04-12 |
US20160213770A1 (en) | 2016-07-28 |
US9764021B2 (en) | 2017-09-19 |
US20120100177A1 (en) | 2012-04-26 |
CA2757224C (en) | 2016-12-06 |
IL215239A0 (en) | 2011-12-29 |
JP2012521747A (ja) | 2012-09-20 |
PL2411503T3 (pl) | 2018-01-31 |
BRPI1010283A2 (pt) | 2016-10-11 |
RU2011143381A (ru) | 2013-05-10 |
KR20110127714A (ko) | 2011-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2646320T3 (es) | Salmonella enterica que presenta un N-glicano de C. Jejuni o derivados del mismo | |
Okoro et al. | Signatures of adaptation in human invasive Salmonella Typhimurium ST313 populations from sub-Saharan Africa | |
Wiles et al. | Organ specificity, colonization and clearance dynamics in vivo following oral challenges with the murine pathogen Citrobacter rodentium | |
Lopez et al. | Virulence factors enhance Citrobacter rodentium expansion through aerobic respiration | |
US20230250138A1 (en) | Virulence Attenuated Bacteria Based Protein Delivery | |
Hartmann et al. | Genes involved in Cronobacter sakazakii biofilm formation | |
Que et al. | Salmonella pathogenicity island 1 (SPI-1) at work | |
Kingsley et al. | Genome and transcriptome adaptation accompanying emergence of the definitive type 2 host-restricted Salmonella enterica serovar Typhimurium pathovar | |
González Barrios et al. | Autoinducer 2 controls biofilm formation in Escherichia coli through a novel motility quorum-sensing regulator (MqsR, B3022) | |
Vallance et al. | Mice lacking T and B lymphocytes develop transient colitis and crypt hyperplasia yet suffer impaired bacterial clearance during Citrobacter rodentium infection | |
Langridge et al. | Simultaneous assay of every Salmonella Typhi gene using one million transposon mutants | |
Harvey et al. | Salmonella enterica serovar typhimurium colonizing the lumen of the chicken intestine grows slowly and upregulates a unique set of virulence and metabolism genes | |
Jiang et al. | Characterization of UDP-glucose dehydrogenase and UDP-glucose pyrophosphorylase mutants of Proteus mirabilis: defectiveness in polymyxin B resistance, swarming, and virulence | |
Lim et al. | IscR is a global regulator essential for pathogenesis of Vibrio vulnificus and induced by host cells | |
Pullinger et al. | Norepinephrine augments Salmonella enterica-induced enteritis in a manner associated with increased net replication but independent of the putative adrenergic sensor kinases QseC and QseE | |
Yang et al. | Characterization of the invasive, multidrug resistant non-typhoidal Salmonella strain D23580 in a murine model of infection | |
Buckner et al. | Beyond antimicrobial resistance: evidence for a distinct role of the AcrD efflux pump in Salmonella biology | |
Whitaker et al. | Loss of sigma factor RpoN increases intestinal colonization of Vibrio parahaemolyticus in an adult mouse model | |
Ilg et al. | O-antigen-negative Salmonella enterica serovar Typhimurium is attenuated in intestinal colonization but elicits colitis in streptomycin-treated mice | |
Cohen et al. | Pathoadaptation of the passerine-associated Salmonella enterica serovar Typhimurium lineage to the avian host | |
Mudrak et al. | The Vibrio cholerae Pst2 phosphate transport system is upregulated in biofilms and contributes to biofilm-induced hyperinfectivity | |
Tsolis et al. | SspA is required for lethal Salmonella enterica serovar Typhimurium infections in calves but is not essential for diarrhea | |
Elfenbein et al. | Novel determinants of intestinal colonization of Salmonella enterica serotype typhimurium identified in bovine enteric infection | |
Elder et al. | Genomic organization and role of SPI-13 in nutritional fitness of Salmonella | |
Haneda et al. | The capsule-encoding viaB locus reduces intestinal inflammation by a Salmonella pathogenicity island 1-independent mechanism |